© 2020 MJH Life Sciences, Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy
Evaluating the Potential for CAR T Cells as Treatment of Solid Tumors
June 15, 2020
Prasad S. Adusumilli, MD, FACS, discusses the potential role of chimeric antigen receptor T-cell therapy as treatment of solid tumors now that they have demonstrated safety and efficacy in some Hematologic Malignancies.
CAR T Cells May Be Safely Administered in Outpatient Setting for Patients With B-Cell Lymphomas
June 10, 2020
In an interview with Targeted Oncology, David G. Maloney, MD, PhD, discussed findings from administration of chimeric antigen receptor T-cell therapy in the outpatient setting for patients with B-cell lymphomas.
Optimized Tandem CAR T-Cell Therapy Targeted CD19/CD20 Appears Feasible in B-NHL
June 02, 2020
Although many of the patients in the study had heavy tumor burden, were in poor physical condition, or had highly aggressive characteristics, they were still able to achieve a satisfactory overall response rate and complete response rate with the tandem CD19/CD20 CAR-engineered T-cell therapy.
Novel CAR-T Cell Therapy Combination Shows Preliminary Activity in R/R B-cell Lymphoma
May 30, 2020
A pair of off-the-shelf CAR T-cell agents have shown promise for the treatment of relapsed/refractory large B-cell or follicular lymphoma, according to the phase 1 ALPHA study.
Integrating EMR Into the Clinical Management of CAR T-Cell Therapy Improves Patient Care
May 14, 2020
In an interview with Targeted Oncology, Andrea Price, APN, discussed the importance of integrating the electronic medical record team into the clinical care team for the treatment of patients with cancer receiving CAR T-cell therapy.
FDA Halts Review of BLA for Ide-cel in R/R Multiple Myeloma Pending Additional Data
May 13, 2020
The review of the Biologics License Application for idecabtagene vicleucel has been put on hold. The FDA issued a Refusal to File letter due to the need for additional data from the developer of the drug.
Protocol Management, Off-the-Shelf Therapies Help Bring CAR T Into More Settings
May 12, 2020
Relevant professional meetings and oncology publications exploded with research and news about chimeric antigen receptor T cells, and this cellular therapy strategy is now being explored across hematologic and solid malignancies.
Higher CAR T-Cell Dosage Improves Efficacy Without Toxicity in Relapsed or Refractory CLL
May 10, 2020
Patients with relapsed or refractory chronic lymphocytic leukemia who received a higher dose of CAR T cells, achieved complete responses, regardless of cell dose, which was highly correlated with long-term survival.
FDA Extends Target Action Date for Liso-cel in R/R Large B-cell Lymphoma
May 06, 2020
The FDA extended the Prescription Drug User Fee Act target action date for liso-cel due to the submission of additional information by the drug developer, which will require additional time to review.
Exploring the Current Role of CAR T Cells in Acute Lymphoblastic Leukemia
May 01, 2020
Jae Park, MD, discusses his key takeaways from chimeric antigen receptor T cells in the treatment landscape of patients with acute lymphoblastic leukemia.